The present invention discloses a combination of vaccine strains for treating, preventing, relieving or controlling Canine Distemper, Canine Parvovirus Enteritis and Canine Infectious Hepatitis, comprising: Canine Distemper virus vaccine strain with the microorganism deposition accession number CGMCC No. 19397, Canine Parvovirus vaccine strain with the microorganism deposition accession number CGMCC No. 19398 and Canine Infectious Hepatitis virus vaccine strain with the microorganism deposition accession number CGMCC No. 19396. The three vaccine strains of the combination of vaccine strains are low in toxicity and good in immunogenicity. The present invention further discloses a live vaccine composition using the above-mentioned combination of vaccine strains as immunogen. The vaccine composition is safe and effective.

The present invention discloses a combination of vaccine strains for treating, preventing, relieving or controlling Canine Distemper, Canine Parvovirus Enteritis and Canine Infectious Hepatitis, comprising: Canine Distemper virus vaccine strain with the microorganism deposition accession number CGMCC No. 19397, Canine Parvovirus vaccine strain with the microorganism deposition accession number CGMCC No. 19398 and Canine Infectious Hepatitis virus vaccine strain with the microorganism deposition accession number CGMCC No. 19396. The three vaccine strains of the combination of vaccine strains are low in toxicity and good in immunogenicity. The present invention further discloses a live vaccine composition using the above-mentioned combination of vaccine strains as immunogen. The vaccine composition is safe and effective.

The present invention provides a recombinant measles virus useful as a live vaccine against COVID-19 and a vector used for production of the recombinant measles virus. That is, the present invention relates to a recombinant measles virus having a gene encoding a protein of the coronavirus SARS-COV-2 inserted between the N gene region and the P gene region in a measles virus genome; the recombinant measles virus in which the protein is a spike protein of SARS-COV-2 or a partial protein thereof; and a DNA in which a gene encoding a protein of SARS-COV-2 is inserted in a region ranging from the 1,686th base to the 1,694th base of a base sequence set forth in SEQ ID NO: 2.